Mortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort

Leonor Mendonça Almeida, Ana Luísa Fernandes, Catarina Gouveia Cardoso, Bruno Lima, Inês Neves, Hélder Novais-Bastos, Patricia Caetano Mota, Natália Melo, Conceição Souto Moura, Susana Guimarães, André Carvalho, Rui Cunha, José Miguel Pereira and António Morais

Abstract

Background: Fibrotic hypersensitivity pneumonitis (fHP) is associated with significant morbidity and mortality. Interstitial lung disease–gender-age-physiology (ILD-GAP) performance in fHP outside the initial cohort was never performed.

Aim: To assess the ILD-GAP index’s ability to predict mortality in a Portuguese cohort of patients with fHP and analyse whether other clinical variables add value.

Methods: Retrospective analysis of fHP cohort in two Portuguese ILD centres. The baseline ILD-GAP index was calculated. Survival was analysed in months; mortality was the primary outcome. Univariate and multivariate analyses to identify mortality risk factors were performed.

Results: A total of 141 patients were included. Fifty-three patients (37.6%) died during the follow-up. The usual interstitial pneumonia (UIP) pattern was found in 49.6%, and their survival was inferior to non-UIP [32 months (interquartile range, IQR = 19, 60) versus 52 months (IQR = 28, 98), p = 0.048]. Patients with an ILD-GAP index higher than three double their risk of mortality [hazard ratio (HR) = 6.48, 95% confidence interval (CI) = [3.03–13.96]] when compared with the patients with an index between 2 and 3 [HR = 3.04, 95% CI = [1.62–5.71]] adjusting for acute exacerbation history. Even though UIP patients had worse survival, it did not reach statistical significance when UIP pattern was added to this model. Acute exacerbation history was an independent risk factor for mortality; however, ILD-GAP still predicted mortality after adjusting for this factor. PaO2 and 6-minute walk test desaturation were not significant risk factors.

Conclusion: ILD-GAP index is a good predictor for mortality in fHP, even after adjusting for other mortality risk factors.

Keywords: chronic hypersensitivity pneumonitis, fibrotic interstitial lung disease, ILD-GAP

Received: 22 February 2022; revised manuscript accepted: 11 October 2022.

Introduction

The prevalence of hypersensitivity pneumonitis (HP) varies widely, ranging from 2% to 47% among interstitial lung diseases (ILD) in different registries.1–5 The HP classic division into acute, subacute, and chronic forms is outdated, and recently, a new classification into acute/ cellular versus chronic/fibrotic subtypes has been proposed.6 In this line, the recently published HP diagnosis guideline highlights the importance of subdividing into two phenotypes: acute/non-fibrotic and chronic/fibrotic.7

It has been recognized that the chronic forms are predominant,8–11 and among the different behaviour patterns,12 some of them have a
progressive fibrosing phenotype, resembling idiopathic pulmonary fibrosis (IPF).9,10,13 In the era of antifibrotic therapy, it is of utmost importance to identify such patients,14 ideally, before substantial clinical and functional decline got established.

The gender-age-physiology (GAP)15 model was designed and validated in IPF and, posteriorly, the analysis of its performance was extended to other ILDs with the publication of ILD-GAP.16 ILD-GAP was created by adding an ILD subtype variable (connective tissue disease-ILD, chronic HP, idiopathic non-specific interstitial pneumonia and unclassifiable ILD) to the original GAP model that accounted for better adjusted survival in these patients. ILD-GAP index is divided in 0–1, 2–3, 4–5, and >5 stages that predict mortality risks at 1, 2, and 3 years. For example, indexes below 3 have a 1-year mortality risk inferior to 8.8%; however, above 4, the mortality risk significantly increases and these patients can be referred to transplant, if appropriate.16 Nevertheless, its performance was evaluated in other ILD;17,18 to our knowledge, it was never evaluated and published in the subset of chronic/fibrotic HP outside the initial cohort. This study aimed to assess ILD-GAP index’s ability to predict mortality in a Portuguese cohort of fibrotic HP (fHP) patients and analyse whether other clinical variables can have additional value.

Materials and methods

Study population
A retrospective analysis of patients with fHP, in two Portuguese ILD centres [Centro Hospitalar Universitário São João-Porto (CHUSJ) and Hospital Pedro Hispano-Matosinhos (HPH)] was accomplished. The diagnosis of HP was made according to clinical presentation, exposure, thoracic high-resolution computed tomography (HRCT), bronchoalveolar lavage (BAL) fluid, and flow cytometry and lung biopsies, as previously published.11 All diagnoses were established in the multidisciplinary team (MDT) meeting. Patients in whom baseline ILD-GAP calculation was not feasible were excluded from the analysis. This study had the approval of the local Ethics Committee in both centres.

Measurements
Baseline demographic data (age, sex, symptoms, smoking status, antigen exposure) and pulmonary function testing, 6-minute walk test (6-min WT), and oxygen arterial pressure (PaO₂) at diagnosis were recorded. Accordingly, the ILD-GAP index was calculated, and medical chart review was assessed to obtain data from BAL, lung biopsy, immunosuppressive therapy, and acute exacerbation events.

HRCTs at diagnosis were reviewed by two experienced thoracic radiologists. The combination of centrilobular nodules, ground-glass infiltration, mosaic attenuation, and middle or upper lobe distribution was considered typical for HP. Fibrotic changes included reticular pattern, traction bronchiectasis, and honeycombing.11 Usual interstitial pneumonia (UIP) pattern was described according to the Fleischner Society terminology.19 Biopsy samples (transbronchial cryobiopsy or surgical lung biopsy) were independently observed and evaluated by two pathologists. HP diagnosis was based on the presence of centrilobular and perilobular fibrosis, bridging fibrosis, centrilobular fibroblastic foci, granulomas, mononuclear chronic interstitial inflammation, and organizing pneumonia. If two or more findings were present, the biopsy was considered high confidence; if only one feature was present, it was considered low confidence.11 The UIP pattern in fHP includes patchy collagen subpleural fibrosis, fibroblast foci, and associated subpleural-dominant honeycombing.

Time to mortality was the primary endpoint. All the patients were followed up from the first to the last visit, lung transplantation, or death.

Statistical analysis
Data are presented as mean (and standard deviation), when continuous, or as counts (and frequencies), when categorical. UIP versus non-UIP mean values of continuous variables were compared with independent sample t-tests, and their categorical variables’ frequencies were compared with chi-square or Fisher’s exact tests (when appropriate).

Survival was analysed with time (in months) from diagnosis to dead (primary outcome) censored by the end of follow-up or transplantation.
Kaplan–Meier curves were used for survival estimates and compared with the log-rank test. Univariate and multivariate Cox proportional hazards regressions were used to identify variables that predict survival status and hazard ratios and their 95% confidence intervals computed. A final Cox regression model with forward conditional stepwise selection was obtained. A final Cox regression model was obtained through forward conditional stepwise selection. The proportional hazards assumption for the final Cox regression model was also tested. ILD-GAP was separated into three groups: ILD-GAP index 0-1, 2-3, and >3. Statistical significance was established at $p < 0.05$. All statistical analysis and graphical representations were performed in Rstudio, an environment for R programming language.

**Results**

**Patient characteristics**

A total of 141 patients with fHP were included in the analysis after assessing all the including criteria. The cohort baseline characteristics are presented in Table 1. The patients’ mean age was 64.7 years, 61% ($n = 86$) were female, and 21.3% ($n = 30$) had a smoking history. Avian exposure was the most frequently reported (66.7%), and 21.3% ($n = 30$) of the patients had an undetermined exposure. Regarding BAL fluid, the mean lymphocyte count was $30.9\% \pm 21.3\%$. Of all patients included, 36.2% ($n = 51$) had been submitted to lung biopsy, 49% ($n = 25$) with transbronchial lung cryobiopsy, 41.2% ($n = 21$) with surgical lung biopsy, and 9.8% ($n = 5$) with CT transthoracic biopsy. Concerning treatment options, 13.2% ($n = 18$) were under vigilance and antigen eviction, 17.6% ($n = 24$) were under steroids, and 69.1% ($n = 94$) were under immunosuppressive therapy with azathioprine, mycophenolate, or rituximab. The median follow-up time was 40 [interquartile range (IQR) = 22, 85] months. Fifty-three patients (37.6%) died during the follow-up, and 11 (7.8%) were submitted to lung transplant.

**UIP versus non-UIP patients**

Due to the high relevance of the UIP pattern in fibrotic ILD regarding prognosis, this pattern was considered and found in 70 (49.6%) patients. The UIP diagnosis was based in imaging in 31 patients (44.3%) and in 39 patients (55.7%) a biopsy sample was needed. Table 1 outlines the differences between UIP and non-UIP patients. We found that UIP had a statistically significant lower total lung capacity ($73.2\% \pm 19\%$ versus $81.6\% \pm 17.2\%$, $p = 0.009$) and lower BAL lymphocyte counts ($23.6\% \pm 19.4\%$ versus $38.3\% \pm 20.7\%$, $p < 0.001$). In 6-min WT, both groups had similar walking distances; however, non-UIP patients had slightly higher, although significant, oxygen desaturation values. Considering therapeutics, UIP patients had a significantly higher percentage of patients under immunosuppressants (Table 1). Regarding survival, the population of non-UIP patients had significantly better survival than UIP patients (Figure 1), with a median follow-up time of 52 months (IQR = 28, 98) compared with 32 months (IQR = 19, 60) in the UIP group ($p = 0.048$).

**The ILD-GAP model performance in fHP cohort/ disease severity and mortality**

In this fHP cohort, the ILD-GAP index is a good predictor of mortality (Figures 2 and 3). The results from univariate Cox regression analyses are presented in Table 2. PaO$_2$ and 6-min WT were not statistically significant risk factors for mortality. However, we found statistically significant associations for other lung function parameters. A final multivariate Cox regression model was built with forward conditional stepwise selection of variables with a $p$-value lower than 0.1 in the univariate analysis. Hence, in the multivariate Cox regression analyses, the ILD-GAP index is a statistically significant risk factor for mortality after adjusting for acute exacerbation (Table 3). Patients with an ILD-GAP index higher than three double their risk of mortality [hazard ratio (HR) = 6.48, 95% confidence interval (CI) = (3.03–13.9)] when compared with the patients with an index between 2 and 3 [HR = 3.04, 95% CI = (1.62–5.71)] having as reference those patients with an index 0–1. From this multivariate model, we can also observe that acute exacerbation is an independent and statistically significant risk factor for mortality in this cohort of patients. When the UIP pattern was added to this model, it did not reach statistical significance.

**Discussion**

ILD-GAP index showed to be a good predictor for mortality in this cohort of fHP patients. In
Table 1. Descriptive statistics of fHP cohort and comparison between UIP and non-UIP patients.

|                          | N = 141* | UIP, N = 70 | Non-UIP, N = 71 | p-value |
|--------------------------|---------|------------|-----------------|---------|
| Age (years)              | 64.7 ± 12.0 | 66.0 ± 11.1 | 63.4 ± 12.8     | 0.2     |
| Sex                      |          |            |                 |         |
| Female                   | 86 (61.0%) | 37 (52.9%) | 49 (69.0%)      |         |
| Male                     | 55 (39.0%) | 33 (47.1%) | 22 (31.0%)      |         |
| Ever-smoker              | 30 (21.3%) | 18 (25.7%) | 12 (16.9%)      | 0.3     |
| Exposure                 |          |            |                 | 0.073   |
| Birds                    | 94 (66.7%) | 40 (57.1%) | 54 (76.1%)      |         |
| Moulds                   | 12 (8.5%)  | 8 (11.4%)  | 4 (5.6%)        |         |
| Cork                     | 4 (2.8%)   | 2 (2.9%)   | 2 (2.8%)        |         |
| Isocyanates              | 1 (0.7%)   | 0 (0.0%)   | 1 (1.4%)        |         |
| Undefined                | 30 (21.3%) | 20 (28.5%) | 10 (14.1%)      |         |
| Lung function            |          |            |                 |         |
| FEV1 (%)                 | 81.3 ± 23.4 | 78.9 ± 22.0 | 83.8 ± 24.6     | 0.2     |
| FVC (%)                  | 77.7 ± 22.2 | 74.6 ± 22.1 | 80.8 ± 21.9     | 0.10    |
| TLC (%)                  | 77.5 ± 18.5 | 73.2 ± 19.0 | 81.6 ± 17.2     | 0.009   |
| DLCO (%)                 | 47.3 ± 18.5 | 44.9 ± 17.5 | 49.5 ± 19.3     | 0.2     |
| PaO₂f                    | 72.5 ± 12.8 | 73.0 ± 13.2 | 71.9 ± 12.5     | 0.6     |
| 6-min WT                 |          |            |                 |         |
| Distance (m)             | 383.0 ± 105.2 | 395.6 ± 102.5 | 369.8 ± 107.2 | 0.2     |
| Desaturation (%)         | 9.4 ± 6.1  | 8.0 ± 5.7  | 10.7 ± 6.2      | 0.021   |
| Bronchoalveolar lavage fluid |    |            |                 |         |
| Lymphocytes (%)          | 30.9 ± 21.3 | 23.6 ± 19.4 | 38.3 ± 20.7     | <0.001  |
| Neutrophils (%)          | 7.9 ± 7.3   | 7.7 ± 6.5  | 8.3 ± 8.8       | 0.7     |
| Eosinophils (%)          | 3.8 ± 4.4   | 3.8 ± 4.2  | 3.7 ± 4.7       | >0.9    |
| UIP case definition      |          |            |                 |         |
| Imaging                  | 31 (44.3%) |            |                 |         |
| Histology                | 39 (55.7%) |            |                 |         |
| Therapeutics             |          |            |                 | <0.001  |
| Vigilance ± antigen avoidance | 18 (13.2%) | 5 (7.1%)   | 13 (19.7%)      |         |
| Steroids                 | 24 (17.6%) | 7 (10.0%)  | 17 (25.8%)      |         |

(Continued)
addition, acute exacerbation was also statistically significant risk factor for mortality. Nevertheless, ILD-GAP index was still statistically associated with mortality after adjusting for acute exacerbation. Baseline PaO₂ and 6-min WT were not significant risk factors for mortality and, therefore, were not included in our final Cox regression model. However, when looking at UIP patients, their survival is significantly shorter than non-UIP patients, the presence of this pattern did not add mortality risk to the one predicted by the ILD-GAP index.

GAP index and staging system were initially described and validated for IPF before the approval of antifibrotic therapy and represented a useful mortality risk prediction tool, allowing better communication with patients and helping the lung transplant referral.\(^15\) The GAP model applicability in ILD was subsequently extended with ILD-GAP, validated in major chronic ILD subtypes, including chronic HP.\(^16\) Hyldgaard \textit{et al}.\(^17\) showed that ILD-GAP and Disease Behaviour Classification had good prognostic performance in unclassifiable ILD and were independent of one another in their association with outcome. In rheumatoid arthritis–associated ILD (RA-ILD), GAP model also demonstrated a good discrimination power for mortality risk, and this was not improved by adding rheumatoid factor positivity and UIP pattern on HRCT.\(^18\) Notwithstanding, in myositis-associated ILD, this model showed poor prognostic performance, and the authors explained that the weight of pulmonary function in ILD-GAP might not be adequate for assessing disease severity in myositis.\(^20\) However, these authors focused their analysis on the first 3 years of predicted mortality and did not refer if, in extended follow-up, ILD-GAP index would be a good mortality discriminator.

Regarding UIP pattern shorter survival, as in other chronic HP cohorts,\(^21\) it did not add risk to ILD-GAP in the multivariate analysis. This might be, in part, explained by the sample size, although Morisset \textit{et al}.\(^18\) found similar results in RA-ILD. Since the UIP pattern in histology was also related to poorer survival in other cohorts,\(^13,22,23\) we

|                              | \(N=141^*\) | UIP, \(N=70\) | Non-UIP, \(N=71\) | \(p\)-value |
|------------------------------|-------------|---------------|-------------------|-------------|
| Immunosuppressive therapy    |             |               |                   |             |
|                              | 94 (69.1%)  | 58 (82.9%)    | 36 (54.5%)        |             |
| Acute exacerbation history\(^c\) | 17 (12.2%)  | 11 (15.7%)    | 6 (8.7%)          | 0.3\(^b\)   |
| ILD-GAP index                |             |               |                   | 0.32\(^l\)  |
| 0–1                          | 79 (56.0%)  | 32 (45.7%)    | 47 (66.2%)        |             |
| 2–3                          | 47 (33.3%)  | 27 (38.6%)    | 20 (28.2%)        |             |
| >3                           | 15 (10.6%)  | 11 (15.7%)    | 4 (5.6%)          |             |

DLCO, diffusion capacity of carbon monoxide; fHP, fibrotic HP; FEV₁, forced expiratory volume in the 1st second; FVC, forced vital capacity; ILD-GAP, interstitial lung disease–gender-age-physiology; PaO₂, oxygen arterial pressure; TLC, total lung capacity; UIP, usual interstitial pneumonia; 6-min WT, six-minute walk test.

\(^a\)Student’s \(t\)-test; \(^b\)Chi-square test; \(^c\)\(n=139\); \(^d\)\(n=133\); \(^e\)\(n=131\); \(^f\)\(n=124\); \(^g\)\(n=112\); \(^h\)\(n=106\); \(^i\)\(n=118\); \(^j\)\(n=83\); \(^k\)\(n=136\); \(^l\)Chi-square test for trend; \(^*\)Statistics: mean (± SD) or \(n\) (%).
The desaturation in 6-min WT has prognostic value in fibrotic ILD, so we hypothesized that PaO2 levels or desaturation in 6-min WT could add value to ILD-GAP in predicting mortality. Nevertheless, in our cohort, they were not associated with mortality. On the contrary, we found a slight, though significant, desaturation in non-UIP patients; yet it did not seem clinically relevant.

Concerning BAL fluid analysis, lymphocytosis was significantly superior in the non-UIP group, which have been associated with a better prognosis.

This study has several limitations, namely its retrospective nature. More detailed data about HRCT, such as the extension of fibrosis, or echocardiogram, could have enriched the analysis. Another limitation is the lack of comparison between treated and untreated patients and the analysis of treatment as an independent risk factor for mortality. Even though the efficacy of corticosteroids in fHP is not adequately evaluated, its use is widely adopted due to the reports from the acute form of the disease. In our centre, immunosuppressive treatment, mainly with azathioprine or mycophenolate mofetil, is generally the first approach. However, concurrent steroids are first administered, frequently for a short period of time, in very symptomatic patients. We have shown that azathioprine can improve lung function in fHP, however, the impact on survival is not studied. In this cohort, there were different treatment durations and several patients treated with more than one drug sequentially, either due to side effects or progression of disease, which precluded the analysis of impact of treatment in survival.

Nonetheless, the data were derived from two ILD centres, combining an academic and a non-academic hospital, thereby increasing their reliability.

Finally, our study suggests that the ILD-GAP index can be used as a mortality risk prediction tool in fHP. ILD-GAP is an extremely easy to perform index, which enhances its applicability in every day clinical practice. Moreover, it is applied at diagnosis and allows identification of patients more likely to have a worse prognosis, which is exceedingly relevant in the era of progressing pulmonary fibrosis with access to anti-fibrotic therapy.
Table 2. Factors associated with mortality in unadjusted univariate Cox proportional regression models.

|                                  | HR   | 95% CI      | p-value |
|----------------------------------|------|-------------|---------|
| Age (years)                      | 1.04 | 1.02–1.06   | <0.001  |
| Sex (male)                       | 1.31 | 0.76–2.26   | 0.33    |
| Ever-smoker                      | 0.89 | 0.43–1.83   | 0.75    |
| Antigen identification (yes)     | 0.78 | 0.41–1.49   | 0.46    |
| Lung function                    |      |             |         |
| FEV1 (%)                         | 0.99 | 0.97–1.00   | 0.06    |
| FVC (%)                          | 0.97 | 0.96–0.99   | <0.001  |
| TLC (%)                          | 0.98 | 0.96–0.99   | <0.001  |
| DLCO (%)                         | 0.96 | 0.94–0.97   | <0.001  |
| PaO2                             | 0.99 | 0.96–1.01   | 0.25    |
| 6-min WT                         | 1.00 | 1.00–1.00   | 0.26    |
| Bronchoalveolar lavage fluid     |      |             |         |
| Lymphocytes (%)                  | 0.97 | 0.96–0.99   | <0.001  |
| Neutrophils (%)                  | 1.02 | 0.97–1.07   | 0.45    |
| Eosinophils (%)                  | 0.98 | 0.89–1.08   | 0.70    |
| UIP pattern                      | 2.02 | 1.16–3.53   | 0.01    |
| Acute exacerbation history       | 3.99 | 2.10–7.57   | <0.001  |
| ILD-GAP index                    |      |             |         |
| 0–1                              | Ref  |             |         |
| 2–3                              | 2.72 | 1.47–5.03   | <0.001  |
| >3                               | 6.09 | 2.91–12.77  | <0.001  |

CI, confidence interval; DLCO, diffusion capacity of carbon monoxide; FEV, forced expiratory volume; FVC, forced vital capacity; HR, hazard ratio; ILD-GAP, interstitial lung disease–gender-age-physiology; Ref, reference group; TLC, total lung capacity; UIP, usual interstitial pneumonia; 6-min WT, six-minute walk test.

Table 3. Multivariate Cox regression model obtained by forward conditional stepwise selection.

|                                  | HR   | 95% CI      | p-value |
|----------------------------------|------|-------------|---------|
| ILD-GAP index                    |      |             |         |
| 0–1                              | Ref  |             |         |
| 2–3                              | 3.04 | 1.62–5.71   | <0.001  |
| >3                               | 6.48 | 3.03–13.9   | <0.001  |
| Acute exacerbation history       | 4.4  | 2.28–8.5    | <0.001  |

CI, confidence interval; HR, hazard ratio; ILD-GAP, interstitial lung disease–gender-age-physiology; Ref, reference group.
Declarations

Ethics approval and consent to participate
This study had the approval of the local Ethics Committee in both centres (Centro Hospitalar Universitário São João-Porto and Hospital Pedro Hispano-Matosinhos).

Consent for publication
Not applicable.

Author contributions
Leonor Mendonça Almeida: Conceptualization; Data curation; Formal analysis; Investigation; Writing – original draft; Writing – review & editing.
Ana Luísa Fernandes: Data curation; Investigation; Writing – review & editing.
Catarina Gouveia Cardoso: Data curation; Investigation; Writing – review & editing.
Bruno Lima: Data curation; Formal analysis; Methodology; Software; Writing – review & editing.
Inês Neves: Conceptualization; Investigation; Writing – review & editing.
Hélder Novais-Bastos: Investigation; Writing – review & editing.
Patrícia Caetano Mota: Formal analysis; Investigation; Writing – review & editing.
Natália Melo: Formal analysis; Writing – review & editing.
Conceição Souto Moura: Conceptualization; Writing – review & editing.
Susana Guimarães: Investigation; Writing – review & editing.
André Carvalho: Investigation; Writing – review & editing.
Rui Cunha: Investigation; Writing – review & editing.
José Miguel Pereira: Investigation; Writing – review & editing.
António Morais: Conceptualization; Investigation; Methodology; Project administration; Validation; Writing – review & editing.

Acknowledgements
Not applicable.

Funding
The authors received no financial support for the research, authorship and/or publication of this article.

Competing interests
The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Availability of data and materials
Not applicable.

ORCID iD
António Morais https://orcid.org/0000-0001-8348-8651

References
1. Morell F, Roger À, Reyes L, et al. Bird fancier’s lung: a series of 86 patients. Medicine (Baltimore) 2008; 87: 110–130.
2. Thomeer MJ, Costabe U, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 2001; 32: 114s–118s.
3. Kreuter M, Herth FJ, Wacker M, et al. Exploring clinical and epidemiological characteristics of interstitial lung diseases: rationale, aims, and design of a nationwide prospective registry – the EXCITING-ILD registry. Biomed Res Int 2015; 2015: 123876.
4. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103: 1122–1129.
5. Singh S, Collins BF, Sharma BB, et al. Interstitial lung disease in India. Results of a prospective registry. Am J Respir Crit Care Med 2017; 15: 801–813.
6. Vasakova M, Morell F, Walsh S, et al. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med 2017; 196: 680–689.
7. Raghu G, Wilson KC, Bargagli E, et al. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020; 202: 56–69.
8. Lima MS, Coletta EN, Ferreira RG, et al. Subacute and chronic hypersensitivity pneumonitis: histopathological patterns and survival. Respir Med 2009; 103: 508–515.
9. Vourlekis JS, Schwarz MI, Cherniack RM, et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. *Am J Med* 2004; 116: 662–668.

10. Walsh SL, Sverzellati N, Devaraj A, et al. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. *Eur Radiol* 2012; 22: 1672–1679.

11. Santos V, Martins N, Sousa C, et al. Hypersensitivity pneumonitis: main features characterization in a Portuguese cohort. *Pulmonology* 2020; 26: 130–137.

12. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013; 188: 733–748.

13. Churg A, Sin DD, Everett D, et al. Pathologic patterns and survival in chronic hypersensitivity pneumonitis. *Am J Surg Pathol* 2009; 33: 1765–1770.

14. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med* 2019; 381: 1718–1727.

15. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic. *Ann Intern Med* 2012; 156: 684–691.

16. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. *Chest* 2014; 145: 723–728.

17. Hyldgaard G, Bendstrup E, Wells AU, et al. Unclassifiable interstitial lung diseases: clinical characteristics and survival. *Respirology* 2017; 22: 494–500.

18. Morisset J, Vittinghoff E, Lee BY, et al. The performance of the GAP model in patients with rheumatoid arthritis associated idiopathic lung disease. *Respir Med* 2017; 127: 51–56.

19. Lynch DA, Sverzellati N, Travis WD, et al. Review diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med* 2018; 6: 138–153.

20. Brusca RM, Pinal-Fernandez I, Psoter K, et al. The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. *Respir Med* 2019; 150: 63–65.

21. Ojanguren I, Morell F, Ramón MA, et al. Long-term outcomes in chronic hypersensitivity pneumonitis. *Allergy* 2019; 74: 944–952.

22. Wang P, Jones KD, Urisman A, et al. Pathological findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. *Chest* 2017; 152: 502–509.

23. Ohtani Y, Saiki S, Kitaichi M, et al. Chronic bird fancier’s lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. *Thorax* 2005; 60: 665–671.

24. Chung JH, Montner SM, Adegunsoye A, et al. CT findings associated with survival in chronic hypersensitivity pneumonitis. *Eur Radiol* 2017; 27: 5127–5135.

25. Suzuki AT, Kondoh YA, Brown KEK, et al. Acute exacerbations of fibrotic interstitial lung diseases. *Respirology* 2020; 25: 525–534.

26. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. *Am J Respir Crit Care Med* 2003; 168: 1084–1090.

27. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests reproducibility in fibrotic interstitial pneumonia. *Am J Respir Crit Care Med* 2005; 171: 1150–1157.

28. Mönkäre S. Influence of corticosteroid treatment on the course of farmer’s lung. *Eur J Respir Dis* 1983; 64: 283–293.

29. Kokkarinen JI, Tukiainen HO and Terho EO. The ILD-GAP risk prediction model performs of the GAP model in patients with pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med* 2018; 6: 138–153.

30. Kokkarinen JI, Tukiainen HO and Terho EO. Recovery of pulmonary function in farmer’s lung. A five-year follow-up study. *Am Rev Respir Dis* 1993; 147: 793–796.

31. Terras Alexandre A, Martins N, Raimundo S, et al. Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients. *Pulm Pharmacol Ther* 2020; 60: 101878.

32. Raimundo S, Pimenta AC, Cruz-Martins N, et al. Insights on chronic hypersensitivity pneumonitis’ treatment: Factors associated with a favourable response to azathioprine. *Life Sci* 2021; 272: 119274.

33. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med* 2022; 205: e18–e47.